Pharmaceutical Technology

NOVEMBER 9, 2022

Reimbursement has been a major obstacle in the EU for expensive gene therapies, including bluebird bio’s beta-thalassemia therapy Zynteglo. million price tag. The post Can gene therapies for haemophilia defend their high price tags? After its approval, bluebird had set Zynteglo’s price at roughly EUR1.6 million ($1.8

FDA 111

FDA 111

pharmaphorum

MAY 10, 2022

The FDA awarded a fast-track designation to lecanemab in December and has also given the drug breakthrough tag as a treatment for early-stage Alzheimer’s, and Biogen and Eisai will be hoping the drug can sidestep the controversy that engulfed Aduhelm from the moment it was approved.

FDA 40

FDA 40

pharmaphorum

APRIL 14, 2022

million price tag. bluebird pulled it off the market last year however and retreated from the European market, saying the pricing and reimbursement environment was too hostile to make its business there viable. The gene therapy has already been approved for marketing in the EU and UK, where it was launched at a cost of around $1.7

FDA 63

FDA 63

pharmaphorum

AUGUST 18, 2022

The US approval comes three years after Zynteglo (betibeglogene autotemcel) was approved for the same indication in Europe, and subsequently withdrawn after bluebird concluded that it wasn’t possible to build a commercially viable business for the gene therapy as the pricing and reimbursement environment there was too “hostile.”

FDA 52

FDA Insurance 52

Pharmaceutical Technology

MAY 2, 2023

IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000. Patients and healthcare facilities across markets often experience difficulties getting these agents reimbursed. Cost-related unmet needs also scored highly.

Immunization 52

Immunization Vaccines 52

pharmaphorum

DECEMBER 17, 2021

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

FDA 52

FDA 52

pharmaphorum

JUNE 2, 2022

And of course, in many cases, these drugs have higher than average price tags compared to the wider market which is due to the limited – or in most cases – non-existent competition within a treatment area.”. Raising questions.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

PharmD Live

JANUARY 25, 2022

Patient health improves, as do satisfaction scores and CMS reimbursements. During a Routine Flu Shot, a Pharmacist Saves a Patient’s Life Lisa Boylan |Mar-22-18|Categories: Article |Tags: Pharmacy_Value [link]. Adverse drug events are avoided. 88% report that their EHR produces clinical benefits for the practice. Dean, Troy C.

Adverse Reactions 52

Adverse Reactions Patient Care Communication Hospitals 52

pharmaphorum

NOVEMBER 16, 2022

Yet, in the space of a decade, certain treatments have come along that have raised important questions over the future of treatment, reimbursement, and the value of the quality of life for patients. However, with a price tag of €1.58 How to navigate the new climate. At more than $2.1

131

131

Pharmaceutical Technology

JANUARY 27, 2023

To qualify for a warranty reimbursement, there are three forms that must be filled out and specifically asks for multiple lab values to demonstrate patient response,” he said in an email to Pharmaceutical Technology. Furthermore, he said extracting data to validate the criteria for a warranty reimbursement could be an onerous process.

Documentation 52

Documentation Immunization Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

AUGUST 26, 2022

For now, the list price hasn’t been set and will depend on discussions with reimbursement authorities, according to the biotech. million spread over five years.

FDA 110

FDA 110

European Pharmaceutical Review

MAY 11, 2023

Transformative treatments have exposed and tested the limitations of our value assessment and reimbursement systems. 1 This is assuming a $1M price tag for all gene therapies. Most important lesson learned in developing gene therapy Zolgensma (onasemnogene abeparvovec)? Stakeholder education is critical to achieving this.

FDA 71

FDA 71

pharmaphorum

JUNE 15, 2021

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. But there is a silver lining.

Vaccines 90

Vaccines 90

Pharmaceutical Technology

MARCH 17, 2023

On 16 March, Watt spoke at GlobalData webinar titled “Pharma [POLI]: Market Access Risk Outlook”, providing a current outlook on the pharmaceutical pricing and reimbursement environments around the world, including key reforms, risks and opportunities. GlobalData is the parent company of Pharmaceutical Technology.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Communication 102